{'fraction_non_alphanumeric': 0.03674740233880019, 'fraction_numerical': 0.027080844285145362, 'mean_word_length': 4.928740072977034, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Absent, Small or Homeotic 2-like Protein (ASH2L) Enhances the Transcription of the Estrogen Receptor α Gene through GATA-binding Protein 3 (GATA3)*

Background: ASH2L is a component of MLL complexes conferring H3K4 trimethylation. Results: Increased ASH2L expression induces ERα expression in breast cancers. ASH2L controls estrogen receptor (ER) α expression by directly potentiating GATA3 transcriptional activity. Conclusion: ASH2L enhances ERα expression as a coactivator of GATA3 in breast cancers. Significance: Amplification of the ASH2L gene may contribute to breast cancer development by increasing ERα expression. ASH2L is a component of MLL complexes that confer H3K4 trimethylation. The ASH2L gene is located at 8q11–12, which is often amplified in breast cancers. We found that increased ASH2L expression, which can result from gene amplification, is often correlated with increased ERα expression in both breast cancer cell lines and primary breast cancers. Forced expression of ASH2L induced ERα expression in mammary epithelial cells, whereas depletion of ASH2L suppressed ERα expression in breast cancer cells. To understand the mechanism by which ASH2L regulates ERα expression, we identified GATA3 as the binding protein of ASH2L. ASH2L was shown to potentiate the transcriptional activity of GATA3. ASH2L was recruited to the enhancer of the ERα gene through GATA3 to promote ERα transcription. This study established that ASH2L enhances ERα expression as a coactivator of GATA3 in breast cancers.

Estrogens are indispensable for the development of mammary glands and involved in the growth and development of breast cancers (1). During puberty, ductal growth is largely directed by estrogen (2). During early pregnancy, estrogen and progesterone are responsible for further ductal branching and extensive lobulo-alveolar proliferation (3). Exposure to excessive estrogen increases the risk of breast cancers, whereas estrogen antagonist tamoxifen decreases the incidence of breast cancers (4).
Estrogens exert their cellular effects through estrogen receptor (ER) 2 that is a member of the nuclear receptor superfamily (5). Although there are two estrogen receptors (ER␣ and ER␤) in human, it is ER␣ which plays a major role in breast normal and cancer development (6,7). ER modulates target gene transcription by directly binding to a short DNA sequence, termed the estrogen response element located in the promoter regions of the target genes. Estrogen receptor also modulates gene expression by communicating with other transcription factors such as AP-1 and Sp1 (8,9). About 70% of breast cancers express ER␣. About 70 -80% of ER positive breast cancers are responsive to anti-estrogen therapy (10). However, these tumors gradually become resistant to anti-estrogen agents after several months of anti-estrogen therapy (11). The emergence of anti-estrogen-resistant cancer cells poses a major impediment to the successful treatment of breast cancers.
Expression of the ER␣ gene is under complicated control with at least seven promoters (12). Analysis of ER␣ promoters identified AP2C as an important transcription factor controlling ER expression (13). Other important transcription factors involved in ER␣ expression include FOXM1, FOXO1, GATA3, and NR2E3 (14 -17). In addition to transcriptional regulation, ER␣ is also regulated through mRNA stability and protein stability (18). The ER␣ protein level is suppressed by the treatment of estrogen in normal breast tissues and breast cancers (19). ER␣ expression has been shown to be up-regulated in breast cancers but the underlying mechanisms remain elusive (20).
Here we report that overexpression of ASH2L due to gene amplification induces expression of the ER␣ gene in breast cancers. In an effort to understand the mechanisms by which ASH2L activates the ER␣ gene, we identified GATA3 as an ASH2L interacting protein. We found that ASH2L enhances the transcriptional activity of GATA3, indicating that ASH2L is a coactivator of GATA3. Further studies established that ASH2L promotes ER␣ expression through its enhancer harboring GATA3 binding sites.

MATERIALS AND METHODS
Plasmids and Antibodies-pCMV-sport6-GATA3 and pCMV-ASH2L are IMAGE clones from Open Biosystem (Huntsville, AL). GATA3-TK-Luc reporter vector was generated by inserting an oligonucleotide carrying three GATA3 binding sites into the SalI/HindIII sites of TK-Luc. pGBKT7-ASH2L was generated by inserting ASH2L cDNA into the BamHI site of pGBKT7. Anti-ASH2L was obtained from Bethyl Laboratories (Montgomery, TX). Anti-ER and anti-GATA3 were purchased from Abcam (Cambridge, MA).
Establishment of Mammary Epithelial Cell Line-The inguinal glands were collected from wild type mice. Mammary epithelial cells were separated from stromal cells by collagenase digestion and Percoll gradient centrifugation (44). 5 ϫ 10 6 of 293 FT packaging cells were transfected with 15 g of lentiviral vector for P53DD (Addgene) along with packaging vectors through the calcium phosphate precipitation method. Fortyeight hours after the transfection, viral supernatant was added to 5 ϫ 10 5 mammary epithelial cells with 8 g/ml of Polybrene and incubated for 5 h. Immortalized cells appeared 2 weeks later.
RT-PCR and PCR-Total RNAs were prepared by the TRizol (Invitrogen) method. RT-PCR was performed with SuperScript one-step RT-PCR kit from Invitrogen. Real-time RT-PCR and PCR were performed on ABI 7300 (Applied Biosystems) using SYBR Green Supermix (Applied Biosystems) according to the manufacturer's protocol. The ␤-actin locus was used for the internal reference copy number to determine the ASH2L copy number.
Immunohistochemistry-Immunohistochemical analysis was performed on paraffin-embedded human normal breast or breast cancer tissues. Sections were deparaffinized and rehydrated. After the inactivation of endogenous peroxidase activity and antigen retrieval, sections were blocked with 10% normal bovine serum in phosphate-buffered saline, followed by sequential incubation at room temperature with anti-ASH2L antibodies for 3 h, biotinylated goat anti-rabbit IgG for 1 h, streptavidin-linked horseradish peroxidase for 30 min, and finally 3,3Ј-diaminobenzidine tetrahydrochloride solution for 4 min. Sections were counterstained with hematoxylin.
Generation of Stable Cell Lines Expressing Human ASH2L-The immortalized mammary cells were infected with lentiviruses expressing ASH2L. After selection with blasticidin (10 g/ml), the individual clones were combined, and expanded. The cell extracts were subject to Western blot analysis.
Yeast Two-hybrid Screening-Yeast two-hybrid screening was performed using the matchmaker two-hybrid system kit as instructed by the manufacturer (Clontech). Briefly, the yeast strain HF7C was cotransformed with a human matchmaker mammary gland cDNA expression library and pGBKT7-ASH2L. The HF7C cells were selected by their growth in medium lacking histidine and the expression of ␤-galactosidase. Four days later, the clones that likely contained the ASH2L interacting protein emerged. These clones were confirmed by its expression of ␤-galactosidase.
GST Pull-down Assays-GST and GST fusion proteins were produced in Escherichia coli BL21 and bound to glutathione-Sepharose beads according to the manufacturer's instructions (Pharmacia). In vitro translation was performed using rabbit reticulocyte lysate (Promega) and labeled with [ 35 S]methionine. 50 l of GST fusion protein was incubated with 10 l of in vitro translated proteins for 2 h in 500 l of NETN (20 mM Tris-HCl, pH 7.5, 100 mM KCl, 0.7 mM EDTA, 0.05% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride). Bound proteins were washed 5 times with NETN, eluted by boiling for 2 min in 30 l of protein loading buffer, separated by SDS-PAGE, and autoradiographed.
Immunoprecipitation-HEK293 cells were transfected with GATA3 and ASH2L expression vectors. The nuclear extract was immunoprecipitated by anti-GATA3 or control IgG in GST binding buffer (20 mM Tris-HCl, pH 7.9, 180 mM KCl, 0.2 mM EDTA, 0.05% Nonidet P-40, 0.5 mM PMSF, and 1 mM DTT). After extensive washing using the same buffer, the bound proteins were eluted by boiling in SDS-PAGE sample buffer, resolved by SDS-PAGE, transferred onto a nitrocellulose membrane, and subjected to Western blot analysis using anti-ASH2L.
shRNA Transfection-Five ASH2L shRNA constructs and one mock shRNA (pKLO vector) construct were purchased from Sigma. Lentiviruses were produced by transfecting 293FT cells with shRNA vectors along with packaging vector for 48 h. BT-483 cells were infected for 24 h with viral supernatant and selected for 6 -8 days with 0.5 g/ml of puromycin. The cells were then combined for further analysis.
Enhancer Analysis-The ER␣ enhancer 1 fragment and its mutant fragment with two GATA3 binding sites mutated were amplified from human genome DNA using forward primers, 5Ј-AGACATCCCGGGGATGGTCCTGATTATGG-3Ј and 5Ј-AGACATCCCGGGGATGGTCCTCCCTATGGCCCCC-TGAAATATGCT and the common reverse primer, 5Ј-AGCT-AGAGTCGACGAAAATATTTAGAGATACGG-3Ј, digested with SmaI and SalI, and cloned into the luciferase report vector pGL3-promoter. Immortalized mammary epithelial cells or BT-483 cells (1 ϫ 10 5 ) were plated in DMEM containing 10% fetal calf serum in six-well plates and cultured for 24 h before transfection. Transfections were performed using Lipofectamine 2000 reagent (Invitrogen) with ER-LUC (1.8 g) and pCMV-␤ (0.2 g) as an internal control for transfection efficiency. Cell extracts were prepared 36 h after transfection and assayed for luciferase and ␤-galactosidase activities.
Chromatin Immunoprecipitation (ChIP) and ChIP-qPCR Analyses-BT483 cells were maintained in DMEM containing 10% fetal calf serum. Cells were cross-linked with 1% formaldehyde for 10 min at room temperature. After cells were collected, chromatin immunoprecipitation was performed as described (45) using the appropriate antibodies. The primers used were: F1/R1, 5Ј-GATGGTCCTGATTATGGGAT-3Ј and 5Ј-TATT-TAGAGATACGGAAAAGG-3Ј. The primers were F2/R2, 5Ј-AAATTGTAGGAGAGCTCCGC-3Ј and 5Ј-CCTCTAAGAA-GTTTTTCTACATC-3Ј for the upstream sequence. Purified DNA fragments were amplified and visualized in agarose gel electrophoresis for ChIP analysis. Real-time qPCR was performed as described above for ChIP-qPCR analysis. Each assay was repeated three times. Representative results were presented.

RESULTS
Overexpression of ASH2L Often Correlates to Increased ER␣ Expression-To identify genes that control the expression of ER␣, we searched for genes whose expressions are highly correlated with ER␣ expression in the microarray data from a total of 51 human breast cancer cell lines (46). A close examination of the data revealed that high ER␣ mRNA levels were often associated with high ASH2L mRNA levels (supplemental Table 1S). To confirm this observation, we examined ER␣ and ASH2L mRNA and protein in four ER positive tumor cell lines. Realtime RT-PCR revealed that BT-483 and MDA-MB-134 expressed high ER␣ and ASH2L mRNA, whereas MCF-7 and T47D express relatively low ER␣ and ASH2L mRNA (Fig. 1A). Western blots showed that both the ER␣ and ASH2L proteins correspond to their mRNA level in these four cell lines (Fig. 1A). Both BT-483 and MDA-MB-134 carry amplification of 8p11-12 where the ASH2L gene is located (47,48). As expected, we confirmed that the ASH2L gene is amplified in both BT-483 and MDA-MB-134 cells but not in MCF-7 and T47D cells (Fig.  1A), indicating that ASH2L overexpression in these two cancer cell lines are due to gene amplification. We examined 9 additional breast cancer cell lines for ER␣ and ASH2L expression by real-time RT-PCR. We found that ER negative cells also express ASH2L, indicating that ASH2L alone is not sufficient to activate ER␣ expression (Fig. 1A).
To find if ER␣ expression correlates to ASH2L expression in primary breast cancers, we examined ER␣ mRNA and ASH2L mRNA in a total of 32 cases of ER positive breast cancers. We found that eight cases expressed high levels of ASH2L mRNA. Seven of the eight cases also expressed high levels of ER␣ mRNA, whereas one case expressed a low level of ER␣ mRNA (Fig. 1B), confirming that increased ASH2L expression is associated with increased ER␣ expression in primary breast cancers. We also found that three breast tumors without high ASH2L expression express high levels of ER␣, indicating that other fac-tors can contribute to the high level expression of ER␣. Immunostaining revealed that the ASH2L protein is heterogeneously expressed in the nuclei of normal mammary epithelial cells (Fig.  1B), whereas these breast cancers with high levels of ASH2L mRNA showed rather homogeneous ASH2L protein expression with increased intensity (Fig. 1B).
Increased Expression of ASH2L Induces ER␣ Expression-To demonstrate the involvement of ASH2L in regulation of the ER␣ gene, an immortalized mammary epithelial cell line was infected with lentivirus expressing ASH2L or control empty virus. Blasticidin-resistant clones were combined and analyzed for ASH2L and ER␣ expression. The overexpression of ASH2L was shown by realtime RT-PCR and Western blot (Fig. 2A). The cells overexpressing ASH2L were found to have much increased ER␣ mRNA and protein expression ( Fig. 2A), indicating that ASH2L can induce the expression of ER␣ in mammary epithelial cells.

Depletion of ASH2L Inhibits ER␣ Expression with Reduced Expression of ER␣ Target Genes and Results in Cell Growth
Inhibition of ER Positive Breast Cancers-To examine the effect of ASH2L on ER␣ expression in breast cancer, BT483 cells were infected with two lentiviruses expressing different shRNAs against ASH2L, each of which reduced the ASH2L transcript about 80% compared with controls (Fig. 2B). We found that cells with reduced ASH2L expression showed decreased ER␣ expression (Fig. 2B). We checked the expression of ER target genes pS2 and cathepsin D (CTSD) in response to estrogen. Accordingly, the expression of these genes in response to estrogen was decreased with the depletion of ASH2L (Fig. 2B). We further sought to determine whether estrogen-dependent growth of BT483 cells was affected by depletion of ASH2L. In comparison with control cells, the depletion of ASH2L significantly inhibited the estrogen-dependent growth of BT483 cells (Fig. 2B), suggesting that ASH2L is involved in estrogen-dependent growth of breast cancer cells.
ASH2L Expression Is Also Regulated at Its Protein Level in Breast Cancers-When we examined ASH2L expression in breast cancer cell lines, we found that the ASH2L mRNA level is slightly lower in T47D cells than that in another breast cancer cell line BT20 (Fig. 3A). However, the ASH2L protein level is much higher in T47D cells than that in BT20 cells (Fig. 3B). A pulse-chase experiment revealed that the ASH2L protein in T47D cells is more stable in BT20 cells (Fig. 3C), indicating that in addition to gene amplification, ASH2L expression is also regulated at its protein level.
Identification of GATA3 as an ASH2L Interacting Protein-As ASH2L is a component of MLL/Set complexes, it is likely that ASH2L is recruited to the ER␣ gene by a certain transcription factor to promote ER␣ expression. To identify such a transcription factor, we performed yeast two-hybrid screening using ASH2L as the bait and a human mammary cDNA library as the prey. One of the interacting proteins isolated is GATA3, which has been shown to regulate ER␣ expression (16). The pGBKT7-ASH2L vector allowed yeast growth when co-transformed with pACT2-GATA3 vector but not with control pACT2 vector (Fig. 4A), indicating that ASH2L indeed inter-FIGURE 3. ASH2L expression is regulated at its protein level. A, ASH2L mRNA level in BT20 and T47D cells, as revealed by real-time RT-PCR. *, p Ͻ 0.05 (versus BT20). B, ASH2L protein level in BT20 and T47D cells, as examined by Western blot. C, ASH2L protein is more stable in T47D cells than in BT20 cells, as revealed by pulse-chase analysis. 35 S-Labeled ASH2L was precipitated by anti-ASH2L at several time points following the labeling.  NOVEMBER 7, 2014 • VOLUME 289 • NUMBER 45 acts with GATA3 in yeast. GST pull-down assay was performed to further demonstrate the interaction between GATA3 and ASH2L. In the GST pull-down assay, 35 S-labeled GATA3 specifically interacted with the GST-ASH2L fusion protein (Fig.  4B). The interaction domain was localized to the 100-amino acid carboxyl-terminal fragment of GATA3 (Fig. 4B).

ASH2L as a Coactivator of GATA3
GATA3 Interacts with ASH2L in Vivo-To detect the interaction between GATA3 and ASH2L in vivo, plasmid expressing ASH2L was co-transfected with plasmid expressing GATA3 into 293T cells. The whole cell extract was prepared and used for an immunoprecipitation assay with anti-GATA3 antibody. Later the immunoprecipitated samples were analyzed by Western blot with anti-ASH2L. Signals corresponding to the size of ASH2L protein were only detected in the samples precipitated with anti-GATA3, whereas there was no signal in the samples precipitated with control serum (Fig. 4C), indicating that ASH2L binds to GATA3 in vivo.
ASH2L Potentiates the Transcriptional Activity of GATA3-To investigate the effects of ASH2L on the transcriptional activity of GATA3, we conducted a transient transfection assay with overexpressed ASH2L. As expected, GATA3 enhanced the expression of luciferase controlled by the GATA3 binding element (Fig. 4D). Overexpression of ASH2L leads to about a 2.5-fold increase in the transcription of the reporter gene medi-ated by GATA3 in a dose-dependent manner (Fig. 4D). The result strongly suggested that ASH2L played an important role in determining the transcriptional activity of GATA3.
ASH2L Potentiates the Activity of ER␣ Enhancer-The ER␣ gene is under control of at least seven alternative promoters and two enhancers (Fig. 5A). GATA3 has been shown to be recruited to enhancer 1 (16). To gain insight into the mechanism by which ASH2L regulates the transcription of ER␣ in breast cancers, the enhancer 1 fragment was cloned into a vector carrying a luciferase reporter gene and tested in ASH2L-depleted or control BT483 cells by transfection assays. Unlike the control reporter gene, the enhancer-directed expression of luciferase was decreased in ASH2L-depleted cells (Fig. 5B). The enhancer-directed expression of luciferase was also decreased in GATA3-depleted cells (Fig. 5C), suggesting that GATA3 is indeed involved in the regulation of ER␣ through this enhancer. To further confirm that ASH2L acts on GATA3 to regulate ER␣ gene expression, we transfected the ER␣ enhancer directed reporter gene, ASH2L expression vector, and GATA3 expression vector into immortalized mammary epithelial cells. GATA3 increased the ER␣ enhancer activity. ASH2L further potentiated the GATA3-mediated transcriptional activity (Fig.  5D). To confirm the role of GATA3 in mediating activation of ER␣ enhancer by ASH2L, the two GATA3 binding motifs in FIGURE 5. ASH2L promotes the enhancer activity of the ER␣ gene through GATA3. A, the diagram of ER␣ regulatory elements. The six promoters are indicated from A to F along with two enhancers (EN1 and EN2). Enhancer 1 (EN1) was used for luciferase activity and ChIP assays. B, depletion of ASH2L decreased the activity of ER␣ enhancer. ASH2L-depleted cells (sh2 as described above) or wild type cells expressing control shRNA (control) were transfected with control luciferase reporter (pGL-Luc) or the luciferase reporter directed by ER␣ enhancer (pGL-ER-Luc) and ␤-gal expression vector. Luciferase activity was normalized to ␤-gal activity. **, p Ͻ 0.01 (versus control reporter). ##, p Ͻ 0.01 (versus control shRNA). C, depletion of GATA3 decreased activity of the ER␣ enhancer. BT483 cells were infected with viruses expressing two different shRNAs targeting GATA3 (sh1, sh2) or control shRNA (NS). Real-time RT-PCR was performed to determine GATA3 mRNA levels (left panel). GATA3-depleted cells or wild type cells expressing control shRNA (control) were transfected and analyzed as described in B (right panel). ##, p Ͻ 0.01 (versus control shRNA); **, p Ͻ 0.01 (versus control reporter). D, ASH2L activated ER␣ enhancer through GATA3. Immortalized mammary epithelial cells were transfected with pGL-ER-Luc or mutant pGL-ER-Luc reporters, ␤-gal expression vector, plus ASH2L expression vector and GATA3 expression vector as indicated. ##, p Ͻ 0.01 (versus control); **, p Ͻ 0.01 (versus normal reporter). ER␣ enhancer were mutated. As expected, both GATA3 and ASH2L had a minimal effect on the activity of the mutated ER␣ enhancer (Fig. 5D).
ASH2L Is Recruited to the Enhancer of ER␣-To investigate if ASH2L is recruited to the ER␣ enhancer in the nuclei of living cells, we performed a ChIP assay. The antibodies against ASH2L or GATA3 could efficiently precipitate the enhancer of the ER␣ gene but could not pull down the fragment upstream of the enhancer (Fig. 6A). The depletion of GATA3 decreased the recruitment of GATA3 and ASH2L to the enhancer, whereas the depletion of ASH2L abolished ASH2L binding but retained GATA3 binding at the enhancer, confirming the specificity of the antibodies and indicating the dependence of ASH2L on GATA3 for its binding at the enhancer (Fig. 6A). WDR5 is another component of MLL complexes. ChIP assays with anti-WDR5 revealed the enriched WDR5 binding to the ER␣ enhancer but not to the fragment upstream of the enhancer in wild type cells. Compared with wild type cells, a substantial reduced amplification was seen in ASH2L-or GATA3-depleted cells (Fig. 6A). These results suggested that the complex is recruited to the ER␣ enhancer in breast cancer cells through ASH2L. As ASH2L is a component of protein complexes carrying histone methyltransferase activity, we performed chromatin immunoprecipitation to find if the recruitment of ASH2L alters the methylated status of histones in ER␣ enhancer. We observed a marked increase of H3K4 trimethylation in the ER␣ enhancer in wild type BT483 cells compared with ASH2L or GATA3-depleted BT483 cells (Fig. 6A). Sequential ChIP was performed to find if ASH2L binds to GATA3 on the ER␣ enhancer in breast cancer cells. The eluted chromatin precipitated by anti-GATA3 was subjected to a second immunoprecipitation with anti-ASH2L or control IgG. There was specific enrichment of DNA corresponding to the ER␣ enhancer with anti-ASH2L compared with IgG controls, whereas no enrichment of DNA upstream of ER␣ enhancer was observed (Fig.  6B), indicating that ASH2L and GATA3 form a complex on ER␣ enhancer.

DISCUSSION
ER␣ signaling is critical for normal breast and breast cancer development. ER␣ expression is up-regulated at the mRNA level in breast cancers (20). The mechanisms by which ER␣ expression is regulated in normal breast and up-regulated in breast cancers are not fully understood. In this study, we demonstrated that ASH2L enhances ER␣ expression. We found that ASH2L interacts with GATA3 and potentiates GATA3 transcriptional activity. ASH2L was shown to be recruited to the enhancer of the ER␣ gene through GATA3 to promote ER␣ transcription. This study established that ASH2L enhances ER␣ expression through acting as a coactivator of GATA3.
We found that the high expression of ER␣ is often correlated with increased ASH2L expression in both breast cancer cell lines and primary breast cancers. However, we also observed that one of the primary tumors with high ASH2L expression expressed a low level of ER␣ mRNA. It is likely that other factors in addition to ASH2L are needed to enhance ER␣ expression.
ASH2L is the component of MLL2 and the ASCOM complex (28,49). These two complexes are recruited to ER␣ through MLL2 and PRIP, respectively. Both complexes have been shown to promote ER␣ transcriptional activity. Although ASH2L does not directly interact with ER␣, it may be required for the function of complexes. In addition to regulating ER␣ expression, it could also be required for ER␣ transcriptional activity. So the decreased expression of ER␣ target genes due to ASH2L depletion could result from both decreased ER␣ expression and activity.
GATA3 is a member of the GATA transcription factor family (51,52). In addition to its function in T cell differentiation (53), GATA3 plays an essential role in maintaining the proliferation and differentiation of breast luminal cells (54,55). GATA3 expression along with FOXA1 expression is associated with ER positive luminal breast cancers that tend to have a favorable prognosis (56,57). The molecular mechanism by which GATA3 functions in mammary glands and ER positive breast cancer development remains to be fully defined. Point mutations on the GATA3 protein have been isolated in about 5% ER positive breast cancers (58,59). Although the role of these mutations in ER positive cancer development remains elusive, it indicates that altered GATA3 signaling could contribute to ER positive breast cancer development. As a coactivator of GATA3, ASH2L could contribute to ER positive tumor development through regulating other GATA3 target genes. It FIGURE 6. A, ASH2L is recruited to the ER␣ enhancer and enhances H3K4-trimethylation at the ER␣ enhancer in breast cancers. One pair of primers for the human ER␣ enhancer region (F1/R1) and another pair of primers ϳ2 kb upstream of the ER␣ enhancer (F2/R2) were used in ChIP-qPCR assays. ChIP was performed with BT483 cells expressing nonspecific shRNA (NS), ASH2L shRNA (sh2 as described above), or GATA3 shRNA (sh2 as described above), and anti-ASH2L, anti-H3K4me3, anti-WDR5, anti-GATA3, or control IgG. ##, p Ͻ 0.01 (versus IgG control); **, p Ͻ 0.01 (versus control shRNA). B, ASH2L and GATA3 protein form complexes on the ER␣ enhancer, as revealed by sequential ChIP assays. The firststep ChIP was performed with BT483 cells and anti-GATA3. The second-step ChIP was carried out with the eluate of the initial ChIP and anti-ASH2L or IgG. PCR were performed using primer sets F1/R1 and F2/R2 as described above.
remains to be determined how ASH2L overexpression affects the function of mutant GATA3 in breast cancers.
The increased ASH2L expression in the two breast cancer cell lines we tested are due to ASH2L gene amplification. In addition, our result also showed that ASH2L expression is regulated at the protein level. Immunostaining revealed that ASH2L expression is heterogeneous in normal breast epithelial cells, which could partially result from regulation of the protein level. The dysregulation of ASH2L at the protein level could also contribute to its abnormal expression in breast cancers.
The ASH2L gene is located on 8p11-12, which is amplified in 10 to 15% of human breast cancers (60 -62). Amplification of 8p11-12 has been associated with estrogen receptor positive luminal breast cancers. The 8p11 amplification is complicated as it contains four amplicons, indicating the involvement of multiple genes from 8p11 amplification in breast cancers (47). So far, only ZNF703 has been identified as a candidate oncogene from 8p11-12 amplification (50,63). The search for oncogenes in this region with the transformation assay using MCF-10A cells provided inconclusive results about the role of individual candidate genes (48). MCF-10A is a basal breast epithelial cell line. When ASH2L was overexpressed in MCF-10A cells, we found that ER␣ expression was not induced (data not shown), indicating the cell-type specific role of the ASH2L protein. So given that the amplification is often associated with ER positive tumors, ASH2L could be one of the genes from 8p11-12 amplicons contributing to the tumor development by inducing ER␣ expression.